Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

Media Release

- 19 abstracts on Genmab programs scheduled for presentation at ASH including 3 daratumumab oral presentations and 11 daratumumab poster presentations
- Daratumumab highlights: new data on lenalidomide and pomalidomide combination treatments, updates on monotherapy studies and novel data on immunomodulatory effects of daratumumab
- 5 abstracts on ofatumumab data to be presented

Copenhagen, Denmark; November 5, 2015 – Genmab A/S (OMX: GEN) announced today that 14 daratumumab and 5 ofatumumab abstracts have been accepted for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition December 5-8 in Orlando, Florida. The abstracts are available on the ASH website at www.hematology.org.

“We are delighted that daratumumab will be featured in three oral presentations at the 2015 ASH Annual Meeting. We are particularly looking forward to the presentation of the updated data from the Phase I study of daratumumab in combination with pomalidomide and dexamethasone in relapsed or relapsed and refractory multiple myeloma and the poster presentation describing previously unknown immunomodulatory effects of daratumumab,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “Data from the Phase II study of daratumumab in patients with heavily pretreated relapsed or refractory multiple myeloma, the Phase I/II study of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma will also be presented in oral sessions.”

Daratumumab

Highlights
Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma – Oral presentation, Saturday, December 5

Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results from a Phase 1/2 Study (GEN503) – Oral presentation, Monday, December 7

Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma – Poster presentation, Sunday, December 6

Open-label, Multicenter Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with ≥2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma (MM) – Oral presentation, Monday, December 7

Other abstracts
Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy – Poster presentation, Saturday, December 5

Management of Infusion-related Reactions Following Daratumumab Monotherapy in Patients with ≥3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius) – Poster presentation, Saturday, December 5

Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab – Poster presentation, Monday, December 7
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Quantitative Pharmacologic Perspective – Poster presentation, Monday, December 7

Target-mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis – Poster presentation, Monday, December 7

Analyses of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a PI and an IMID, or Double Refractory to a PI and an IMID – Poster presentation, Monday, December 7

Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab’)2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-mediated Killing and Augments Daratumumab-induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma – Poster presentation, Monday, December 7

Generation and characterization of microvesicles after Daratumumab interaction with myeloma cells – Poster presentation, Saturday, December 5

Expression Profile of CD38 And Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity – Poster presentation, Sunday, December 6

International Validation of a Dithiothreitol (DTT)-based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing – Poster presentation, Monday, December 7

**Ofatumumab**

Risk-adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with CLL/SLL – Poster presentation, Saturday, December 5

A Phase II Study of Ofatumumab-High Dose Methyl-prednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL – Poster presentation, Monday, December 7

A Phase II Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with CLL – Poster presentation, Saturday, December 5

A Phase II Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated CLL – An Update – Poster presentation, Saturday, December 5

Sequential Therapy with Ofatumumab, High Dose Methyl-prednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The HiLO Trial – Poster presentation, Sunday, December 6

**About daratumumab**

Daratumumab is an investigational human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. It induces rapid tumor cell death through multiple immune-mediated mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity, as well as via induction of apoptosis. Five Phase III clinical studies with daratumumab in relapsed and frontline settings are currently ongoing. Additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant diseases on which CD38 is expressed, such as

Genmab A/S
Bredgade 34E
1260 Copenhagen K, Denmark
Tel: +45 7020 2728
Fax: +45 7020 2729
www.genmab.com

Media Release no. 07
Page 2/4
CVR no. 2102 3884
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

smoldering myeloma and non-Hodgkin lymphoma. Daratumumab has been granted Breakthrough Therapy Designation from the US FDA. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

About Ofatumumab (Arzerra®)

Ofatumumab is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of chronic lymphocytic leukemia (CLL) cells and normal B lymphocytes.

In the United States, Arzerra is approved for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. In the European Union, Arzerra is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. In more than 50 countries worldwide, Arzerra is also indicated as monotherapy for the treatment of patients with CLL who are refractory after prior treatment with fludarabine and alemtuzumab.

Please see full Prescribing Information, including Boxed WARNING for Arzerra (ofatumumab).

Arzerra is marketed under a collaboration agreement between Genmab and Novartis.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in clinical development for multiple myeloma and non-Hodgkin's lymphoma, in addition to other clinical programs, and an innovative pre-clinical pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

1 Michel de Weers et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186, p.1840-1848.